

LABORATORY CORP OF AMERICA HOLDINGS  
Form 8-K  
July 27, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**

**July 27, 2016**

**(Date of earliest event reported)**

**LABORATORY CORPORATION OF**  
**AMERICA HOLDINGS**  
**(Exact Name of Registrant as Specified in its Charter)**

**Delaware**  
**(State or other jurisdiction)**

**1-11353**  
**(Commission)**

**13-3757370**  
**(I.R.S. Employer)**

<b>of Incorporation)</b>	<b>File Number)</b>	<b>Identification No.)</b>
<b>358 South Main Street, Burlington, North Carolina</b> (Address of principal executive offices)	<b>27215</b> (Zip Code)	<b>336-229-1127</b> (Registrant's telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure**

On July 27, 2016, Laboratory Corporation of America<sup>®</sup> Holdings (LabCorp<sup>®</sup>) (NYSE: LH) and Sequenom, Inc. (NASDAQ: SQNM) announced that they have entered into a definitive agreement and plan of merger under which LabCorp will acquire all of the outstanding shares of Sequenom in a cash tender offer for \$2.40 per share, or a transaction value of \$302 million, which represents a total enterprise value of approximately \$371 million, including net indebtedness.

A copy of LabCorp's and Sequenom's joint press release is being furnished as Exhibit 99.1 to this Form 8-K.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

99.1 Joint Press Release issued by LabCorp and Sequenom, dated July 27, 2016

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS

Registrant

By: /s/ F. SAMUEL EBERTS III  
F. Samuel Eberts III  
Chief Legal Officer and Secretary

July 27, 2016